Holen Sie sich die Stockscreener-App
20.72
3.03%
0.61
Handel nachbörslich:
20.72
Schlusskurs vom Vortag:
$20.11
Offen:
$20.28
24-Stunden-Volumen:
801.01K
Relative Volume:
1.42
Marktkapitalisierung:
$580.10M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-3.4079
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
-8.07%
1M Leistung:
-20.92%
6M Leistung:
+7.41%
1J Leistung:
-37.83%
1-Tages-Spanne:
$20.01
$22.03
1-Wochen-Bereich:
$19.20
$23.67
52-Wochen-Spanne:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
20.72 | 562.54M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio's (ANAB) "Neutral" Rating Reiterated at UBS Group - MarketBeat
UBS Adjusts Price Target on AnaptysBio to $20 From $18, Maintains Neutral Rating - MarketScreener
What is Wedbush's Estimate for AnaptysBio Q4 Earnings? - MarketBeat
Federated Hermes Inc. Sells 36,910 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Down 9.8%Should You Sell? - MarketBeat
Wedbush Raises AnaptysBio (NASDAQ:ANAB) Price Target to $45.00 - MarketBeat
AnaptysBio Receives Hold Rating from Truist Financial with $20 Target - AInvest
Federated Hermes Inc. Has $154,000 Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Leerink Partnrs Forecasts Stronger Earnings for AnaptysBio - MarketBeat
Wedbush Weighs in on AnaptysBio's Q3 Earnings (NASDAQ:ANAB) - MarketBeat
What moving averages say about AnaptysBio Inc.Downside Control Plan With Support Analysis - Newser
AnaptysBio Reports Q2 2025 Financial Results and Updates - TipRanks
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $45.00 - Defense World
Can machine learning forecast AnaptysBio Inc. recoveryInvestment Timeline and ROI Summary Report - Newser
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - 富途牛牛
AnaptysBio Inc. stock trend forecastSecure Entry Point Finder with Analysis - Newser
Why AnaptysBio Inc. stock attracts strong analyst attentionProven Trading System with Consistent Gains - Newser
AnaptysBio Inc (ANAB) Stock: Uncovering 52-Week Market Trends - investchronicle.com
AnaptysBio's Promising Pipeline and Financial Stability Support Buy Rating - AInvest
AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating - TipRanks
BIT Capital GmbH Purchases Shares of 25,422 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
DCF Advisers LLC Invests $648,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth - AInvest
Wedbush Raises Price Target on AnaptysBio to $45 From $40, Keeps Outperform Rating - MarketScreener
AnaptysBio (ANAB) Target Price Raised by Wedbush | ANAB Stock Ne - GuruFocus
AnaptysBio: Wedbush raises PT to $45 from $40, maintains Outperform rating. - AInvest
AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 18c - StreetInsider
How to recover losses in AnaptysBio Inc. stockFree Expert Verified Stock Trade Ideas - Newser
AnaptysBio (ANAB) Q2 Revenue Jumps 103% - The Globe and Mail
AnaptysBio earnings beat by $0.18, revenue topped estimates - Investing.com Canada
AnaptysBio reports Q2 EPS ($1.34), consensus ($1.58) - TipRanks
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
AnaptysBio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
AnaptysBio Reports Positive Phase 2b Data for Rosnilimab in Rheumatoid Arthritis and Completes Enrollment for Ulcerative Colitis Trial - Quiver Quantitative
Anaptys Delivers Strong RA Trial Results and Eyes $75M Milestone as Pipeline Advances - Stock Titan
Palmoplantar Pustulosis Clinical Trials, Companies, - openPR.com
Palmoplantar Pustulosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., AnaptysBio, Inc., Boeh - Barchart.com
AnaptysBio Inc. Crosses 200 Day MA — Signal or NoiseProfit Focused Stock Screener Results Released - metal.it
Skandinaviska Enskilda Banken AB publ Purchases New Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Palmoplantar Pustulosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., Anaptysbio, Inc., Boeh - Menafn
How many analysts rate AnaptysBio Inc. as a “Buy”Invest confidently with professional advice - Jammu Links News
Is AnaptysBio Inc. stock overvalued or undervaluedSuperior investment outcomes - Jammu Links News
AnaptysBio (NASDAQ:ANAB) Stock Price Down 9.8%Time to Sell? - MarketBeat
What is AnaptysBio Inc. company’s growth strategyMaximize portfolio growth with expert advice - Jammu Links News
What institutional investors are buying AnaptysBio Inc. stockPhenomenal wealth increase - Jammu Links News
How does AnaptysBio Inc. generate profit in a changing economyHigh-impact stock picks - Jammu Links News
What are AnaptysBio Inc. company’s key revenue driversFree Buy/Sell Signal Notifications - Jammu Links News
AnaptysBio Inc. Stock Analysis and ForecastRapidly growing investment returns - Jammu Links News
When is AnaptysBio Inc. stock expected to show significant growthAchieve consistent double-digit growth rates - Jammu Links News
How does AnaptysBio Inc. compare to its industry peersBuild a winning portfolio with smart picks - Jammu Links News
What makes AnaptysBio Inc. stock price move sharplyUnlock exclusive stock market insights - Jammu Links News
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):